MHRA Drug Safety Update: GLP-1 receptor agonists and dual GLP-1/GIP receptor agonists: strengthened warnings
The Medicines and Healthcare products Regulatory Agency (MHRA) has issued a Drug Safety Alert regarding Glucagon-Like Peptide-1 (GLP-1) receptor agonists and dual GLP-1/glucose-dependent insulinotropic polypeptide (GIP) receptor agonists. The product information for all GLP-1 receptor agonists and dual GLP-1/GIP receptor agonists (dulaglutide, exenatide, liraglutide, semaglutide and tirzepatide) has been further updated to highlight the potential [...]
The post MHRA Drug Safety Update: GLP-1 receptor agonists and dual GLP-1/GIP receptor agonists: strengthened warnings appeared first on Community Pharmacy England.
Recent Comments